Selecta Biosciences, Inc. (SELB): Price and Financial Metrics

Selecta Biosciences, Inc. (SELB): $0.88

0.08 (-8.00%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add SELB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#57 of 345

in industry

SELB Price/Volume Stats

Current price $0.88 52-week high $1.99
Prev. close $0.96 52-week low $0.81
Day low $0.81 Volume 2,774,100
Day high $0.94 Avg. volume 979,585
50-day MA $1.11 Dividend yield N/A
200-day MA $1.24 Market Cap 136.77M

SELB Stock Price Chart Interactive Chart >


Selecta Biosciences, Inc. (SELB) Company Bio


Selecta Biosciences, Inc., a clinical-stage biotechnology company, develops targeted therapies that use immunomodulators encapsulated in nanoparticles to induce antigen-specific immune responses to prevent and treat disease. The company was founded in 2007 and is based in Watertown, Massachusetts.


SELB Latest News Stream


Event/Time News Detail
Loading, please wait...

SELB Latest Social Stream


Loading social stream, please wait...

View Full SELB Social Stream

Latest SELB News From Around the Web

Below are the latest news stories about SELECTA BIOSCIENCES INC that investors may wish to consider to help them evaluate SELB as an investment opportunity.

Further weakness as Selecta Biosciences (NASDAQ:SELB) drops 17% this week, taking five-year losses to 85%

We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...

Yahoo | November 14, 2023

Selecta Biosciences Announces Merger with Cartesian Therapeutics

– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – –

Yahoo | November 13, 2023

Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi

WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it has entered into an agreement to transition the manufacturing and development rights and remaining clinical operations of ImmTOR for SEL-212 to its development and commercialization partner, Swedish Orphan Biovitrum AB (publ.) (

Yahoo | October 31, 2023

The Petri Dish: Selecta gets selective with drug programs; Moderna enters 2nd cancer vaccine collab

A Watertown biotech trimmed its pipeline again, setting aside all of its experimental drugs except one. It's the second time the company has cut programs this year. Plus other life sciences news you may have missed.

Yahoo | August 24, 2023

Q2 2023 Selecta Biosciences Inc Earnings Call

Q2 2023 Selecta Biosciences Inc Earnings Call

Yahoo | August 18, 2023

Read More 'SELB' Stories Here

SELB Price Returns

1-mo N/A
3-mo N/A
6-mo -27.27%
1-year -27.27%
3-year -77.61%
5-year -64.94%
YTD N/A
2023 0.00%
2022 -65.34%
2021 7.59%
2020 27.31%
2019 -10.53%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!